- Raw materials
- Antineoplastics
- Irinotecan
- Quality & compliance
- CoA certified
Filters
Filter
Custom request?
Type
Production region
Qualifications
Country of origin
Irinotecan API Manufacturers & Suppliers
19 verified results
When insight is your advantage
Full data, full access, full negotiation power
Total market transparency
|
Supplier trade data access
|
Buyer / supplier flow comparison
Commercial-scale Suppliers
Producer
Produced in
India|
Employees: 5000+
|
Audit Report:
Certifications:
GMP
|
CEP|
MSDS|
BSE/TSE|
ISO9001All certificates
GMP
CEP
MSDS
BSE/TSE
ISO9001
WC
CoA
Distributor
Produced in
World|
Employees: 50
|
Audit Report:
Certifications:
GMP
|
USDMF|
MSDS|
ISO9001|
CoAAll certificates
GMP
USDMF
MSDS
ISO9001
CoA
Take control of your API sourcing
Submit a Special Inquiry and have Pharmaoffer activate verified suppliers.
Distributor
Produced in
China|
Employees: 50+
|
Audit Report:
Certifications:
GMP
|
CEP|
USDMF|
ISO9001|
CoAAll certificates
GMP
CEP
USDMF
ISO9001
CoA
Distributor
Produced in
World|
Employees: 200+
|
Audit Report:
Certifications:
GMP
|
CEP|
USDMF|
MSDS|
BSE/TSEAll certificates
GMP
CEP
USDMF
MSDS
BSE/TSE
CoA
Producer
Produced in
India|
Audit Report:
Certifications:
GMP
|
USDMF|
WC|
CoAAll certificates
GMP
USDMF
WC
CoA
Producer
Produced in
China|
Audit Report:
Certifications:
coa
All certificates
coa
Get full market intelligence report
€399,-
All Irinotecan data. Full access. Full negotiation power
Producer
Produced in
India|
Audit Report:
Certifications:
coa
All certificates
coa
Producer
Produced in
India|
Audit Report:
Certifications:
USDMF
|
CoAAll certificates
USDMF
CoA
Get full market intelligence report
€399,-
All Irinotecan data. Full access. Full negotiation power
Producer
Produced in
United States|
Audit Report:
Certifications:
USDMF
|
CoAAll certificates
USDMF
CoA
Producer
Produced in
China|
Audit Report:
Certifications:
JDMF
|
CoAAll certificates
JDMF
CoA
Producer
Produced in
India|
Audit Report:
Certifications:
GMP
|
USDMF|
WC|
CoAAll certificates
GMP
USDMF
WC
CoA
Producer
Produced in
China|
Audit Report:
Certifications:
USDMF
|
CoAAll certificates
USDMF
CoA
Get full market intelligence report
€399,-
All Irinotecan data. Full access. Full negotiation power
Producer
Produced in
China|
Audit Report:
Certifications:
USDMF
|
CoAAll certificates
USDMF
CoA
Producer
Produced in
India|
Audit Report:
Certifications:
GMP
|
USDMF|
WC|
CoAAll certificates
GMP
USDMF
WC
CoA
Producer
Produced in
India|
Audit Report:
Certifications:
USDMF
|
CoAAll certificates
USDMF
CoA
Producer
Produced in
Finland|
Audit Report:
Certifications:
GMP
|
CEP|
USDMF|
MSDS|
BSE/TSEAll certificates
GMP
CEP
USDMF
MSDS
BSE/TSE
GDP
JMF
JDMF
coa
Take control of your API sourcing
Distributor
Produced in
China|
Audit Report:
Certifications:
coa
All certificates
coa
Producer
Produced in
India|
Audit Report:
Certifications:
GMP
|
CEP|
USDMF|
WC|
CoAAll certificates
GMP
CEP
USDMF
WC
CoA
Producer
Produced in
India|
Audit Report:
Certifications:
GMP
|
USDMF|
WC|
CoAAll certificates
GMP
USDMF
WC
CoA
When insight is your advantage
Full data, full access, full negotiation power
Total market transparency
|
Supplier trade data access
|
Buyer / supplier flow comparison
Trusted by 30,000+ registered pharma professionals:
Reach multinationals, SMEs, compounding pharmacies & more!
Irinotecan | CAS No: 97682-44-5 | GMP-certified suppliers
A medication that supports treatment of metastatic colorectal cancer, extensive small cell lung cancer, and advanced pancreatic cancer, with evaluation ongoing in metastatic or recurrent cervical cancer.
Therapeutic categories
AlkaloidsAntineoplastic AgentsAntineoplastic and Immunomodulating AgentsBCRP/ABCG2 SubstratesCarbohydratesCholinesterase substrates
Generic name
Irinotecan
Molecule type
small molecule
CAS number
97682-44-5
DrugBank ID
DB00762
Approval status
Approved drug, Investigational drug
ATC code
L01CE02
Primary indications
- For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin)
- Also used in combination with cisplatin for the treatment of extensive small cell lung cancer
- Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer
- Also used in combination with fluorouracil and leucovorin for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy
Product Snapshot
- Irinotecan is an injectable small‑molecule cytotoxic API supplied primarily as intravenous solutions or concentrates
- It is used in combination regimens for metastatic colorectal cancer, extensive small cell lung cancer, metastatic pancreatic adenocarcinoma, and is under investigation for metastatic or recurrent cervical cancer
- It is approved in the US, Canada, and EU, with additional investigational programs ongoing
Clinical Overview
Irinotecan (CAS 97682-44-5) is a semisynthetic camptothecin derivative used as an antineoplastic agent in metastatic colorectal cancer, typically in combination with fluorouracil and leucovorin for first‑line therapy. It is also used with cisplatin in extensive small cell lung cancer and with fluorouracil and leucovorin in metastatic pancreatic adenocarcinoma after progression on gemcitabine-based regimens. A liposomal formulation, marketed as Onivyde, received approval for advanced pancreatic cancer in 2015. Irinotecan continues to be investigated in metastatic or recurrent cervical cancer.
The pharmacologic activity arises from inhibition of topoisomerase I, an enzyme that induces reversible single‑strand DNA breaks to relieve torsional stress during replication and transcription. Irinotecan and its active metabolite SN‑38 bind the topoisomerase I–DNA cleavable complex and prevent religation of the nicked DNA strand. When replication forks encounter this stabilized ternary complex, irreversible double‑strand DNA breaks occur. Mammalian cells repair these lesions inefficiently, leading to S‑phase–specific cytotoxicity and apoptosis. The relative contribution of SN‑38 to clinical activity remains incompletely defined.
After intravenous administration, irinotecan undergoes hepatic conversion by carboxylesterases to SN‑38, followed by glucuronidation primarily via UGT1A1. The drug is a substrate for CYP3A isoforms and several transporters including P‑glycoprotein and OATP1B1. Clearance exhibits substantial interpatient variability, partly influenced by UGT1A1 polymorphisms. Elimination occurs through biliary and renal pathways.
Key safety considerations include dose‑limiting neutropenia and late‑onset diarrhea, both associated with elevated SN‑38 exposure. Patients with reduced UGT1A1 activity may experience increased toxicity. Additional concerns include cholinergic symptoms, hepatobiliary effects, and drug–drug interactions involving CYP3A or transporter modulation.
For API procurement, sourcing should ensure control of stereochemistry, lactone–carboxylate equilibrium, and impurity profiles characteristic of camptothecin derivatives. Compliance with region‑specific monographs, reproducible particle characteristics, and validated stability data is essential for formulation and regulatory use.
The pharmacologic activity arises from inhibition of topoisomerase I, an enzyme that induces reversible single‑strand DNA breaks to relieve torsional stress during replication and transcription. Irinotecan and its active metabolite SN‑38 bind the topoisomerase I–DNA cleavable complex and prevent religation of the nicked DNA strand. When replication forks encounter this stabilized ternary complex, irreversible double‑strand DNA breaks occur. Mammalian cells repair these lesions inefficiently, leading to S‑phase–specific cytotoxicity and apoptosis. The relative contribution of SN‑38 to clinical activity remains incompletely defined.
After intravenous administration, irinotecan undergoes hepatic conversion by carboxylesterases to SN‑38, followed by glucuronidation primarily via UGT1A1. The drug is a substrate for CYP3A isoforms and several transporters including P‑glycoprotein and OATP1B1. Clearance exhibits substantial interpatient variability, partly influenced by UGT1A1 polymorphisms. Elimination occurs through biliary and renal pathways.
Key safety considerations include dose‑limiting neutropenia and late‑onset diarrhea, both associated with elevated SN‑38 exposure. Patients with reduced UGT1A1 activity may experience increased toxicity. Additional concerns include cholinergic symptoms, hepatobiliary effects, and drug–drug interactions involving CYP3A or transporter modulation.
For API procurement, sourcing should ensure control of stereochemistry, lactone–carboxylate equilibrium, and impurity profiles characteristic of camptothecin derivatives. Compliance with region‑specific monographs, reproducible particle characteristics, and validated stability data is essential for formulation and regulatory use.
Identification & chemistry
| Generic name | Irinotecan |
|---|---|
| Molecule type | Small molecule |
| CAS | 97682-44-5 |
| UNII | 7673326042 |
| DrugBank ID | DB00762 |
Pharmacology
| Summary | Irinotecan is a camptothecin‑derived antineoplastic agent that targets DNA topoisomerase I, a nuclear enzyme that manages DNA topology during replication and transcription. Irinotecan and its active metabolite SN‑38 stabilize the topoisomerase I–DNA cleavable complex, preventing religation of single‑strand breaks and leading to replication‑associated double‑strand DNA damage. This S‑phase–specific mechanism results in loss of DNA integrity and subsequent apoptotic cell death. |
|---|---|
| Mechanism of action | Irinotecan inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex. The formation of this ternary complex interferes with the moving replication fork, which induces replication arrest and lethal double-stranded breaks in DNA. As a result, DNA damage is not efficiently repaired and apoptosis (programmed cell death) occurs. |
| Pharmacodynamics | Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. Irinotecan is a semisynthetic derivative of camptothecin. Camptothecins interact specifically with topoisomerase I, an enzyme in the cell nucleus that regulates DNA topology and facilitates nuclear processes such as DNA replication, recombination, and repair. During these processes, topoisomerase I relieves torsional strain in DNA by inducing reversible single-strand breaks, allowing single DNA strands to pass through the break. The 3'-DNA terminus of the broken DNA strands bind covalently with the topoisomerase enzyme to form a catalytic intermediate called a cleavable complex. After the DNA is sufficiently relaxed and the strand passage reaction is complete, DNA topoisomerase reattaches the broken DNA strands to form the chemically unaltered topoisomers that allow transcription to proceed. Irinotecan and its active metabolite SN-38 bind to the topoisomerase I-DNA complex and prevent religation of these single-strand breaks. Current research suggests that the cytotoxicity of irinotecan is due to double-strand DNA damage produced during DNA synthesis when replication enzymes interact with the ternary complex formed by topoisomerase I, DNA, and either Irinotecan or SN-38. Mammalian cells cannot efficiently repair these double-strand breaks. The precise contribution of SN-38 to the activity of irinotecan in humans is not known. Irinotecan is cell cycle phase-specific (S-phase). |
Targets
| Target | Organism | Actions |
|---|---|---|
| DNA topoisomerase I, mitochondrial | Humans | inhibitor |
| DNA topoisomerase 1 | Humans | inhibitor |
ADME / PK
| Absorption | The maximum plasma concentration (Cmax) when a dose of 125 mg/m^2 is given to patients with solid tumours is 1660 ng/mL. The AUC (0-24) is 10,200 ng·h/mL. The Cmax when a dose of 340 mg/m^2 is given to patients with solid tumours is 3392 ng/mL. The AUC (0-24) is 20,604 ng·h/mL. |
|---|---|
| Half-life | The half life of irinotecan is about 6 - 12 hours. The terminal elimination half-life of the active metabolite, SN-38 is 10 - 20 hours. |
| Protein binding | 30%-68% protein bound, mainly to albumin. |
| Metabolism | Hepatic. The metabolic conversion of irinotecan to the active metabolite SN-38 is mediated by carboxylesterase enzymes and primarily occurs in the liver. SN-38 is subsequently conjugated predominantly by the enzyme UDP-glucuronosyl transferase 1A1 (UGT1A1) to form a glucuronide metabolite. |
| Route of elimination | The cumulative biliary and urinary excretion of irinotecan and its metabolites (SN-38 and SN-38 glucuronide) over a period of 48 hours following administration of irinotecan in two patients ranged from approximately 25% (100 mg/m2) to 50% (300 mg/m2). |
| Volume of distribution | The volume of distribution of terminal elimination phase is 110 L/m^2 when a dose of 125 mg/m^2 is given to patients with solid tumours. The volume of distribution of terminal elimination phase is 234 L/m^2 when a dose of 340 mg/m^2 is given to patients with solid tumours. |
| Clearance | * 13.3 L/h/m^2 [Dose of 125 mg/m^2, patients with solid tumours] * 13.9 L/h/m^2 [Dose of 340 mg/m^2, patients with solid tumours] |
Formulation & handling
- Irinotecan is formulated exclusively for parenteral use, with low aqueous solubility requiring solubilizers to maintain the active lactone form in injectable solutions.
- The camptothecin lactone ring is hydrolysis‑sensitive, so handling and dilution conditions should minimize pH‑dependent conversion to the inactive carboxylate.
- Solution concentrates are typically stored and shipped under controlled temperatures to preserve stability and prevent lactone degradation during handling.
Regulatory status
| Lifecycle | The API is largely in a post‑patent‑expiry phase, with Canadian and most U.S. protections already lapsed and the final U.S. patent expiring in 2025. In the US, Canada, and EU markets, this positions the product in a mature stage with increasing potential for generic competition. |
|---|
| Markets | US, Canada, EU |
|---|
Supply Chain
| Supply chain summary | Irinotecan’s market traces back to a single originator brand (Camptosar), with subsequent supply now dominated by numerous multinational generic manufacturers and packagers. Branded and generic products are established across the US, Canada, and EU, supported by a broad global injectable‑focused manufacturing base. Most key patents have already expired, with the final US protection ending in 2025, indicating an environment of existing and continuing generic competition. |
|---|
Safety
| Toxicity | Gastrointestinal complications, such as nausea, vomiting, abdominal cramping, diarrhea, and infection. |
|---|
High Level Warnings:
- Known to cause significant gastrointestinal irritation
- Handling should minimize exposure to materials that may aerosolize or generate contact with mucosal surfaces
- Processes should account for the compound’s potential to induce severe diarrhea and related infectious complications, requiring appropriate containment and waste management controls
Certificate of Analysis
A CoA is a document issued by a companies’ QA/QC-department that confirms that a product meets its product specification and is part of the quality control of a product batch. The CoA commonly contains results obtained from laboratory tests of an individual batch of a product. There are different international standards to which a product can be tested, for example: Ph. Eur. | EP – (European Pharmacopoeia) USP – (United States Pharmacopeia)
Irinotecan is a type of Antineoplastics
Antineoplastics are a crucial category of pharmaceutical active pharmaceutical ingredients (APIs) primarily used in the treatment of cancer. These powerful substances inhibit or destroy the growth of cancer cells, thus impeding the progression of malignancies.
Antineoplastics exert their therapeutic effects through various mechanisms. Some APIs interfere with DNA replication, inhibiting the division and proliferation of cancer cells. Others target specific proteins or enzymes involved in tumor growth, effectively blocking their function. Additionally, certain antineoplastic agents induce programmed cell death, known as apoptosis, in cancer cells.
These APIs find application in a wide range of cancer treatments, including chemotherapy, targeted therapy, immunotherapy, and hormone therapy. They are often administered in combination with other drugs to optimize therapeutic outcomes and minimize drug resistance.
Antineoplastics are typically synthesized through complex chemical processes, ensuring high purity and potency. Stringent quality control measures are implemented throughout manufacturing to meet regulatory standards and ensure patient safety.
Although antineoplastics offer significant benefits in treating cancer, they can also cause adverse effects due to their cytotoxic nature. Common side effects include bone marrow suppression, gastrointestinal disturbances, hair loss, and immune system suppression. Close monitoring and supportive care are essential to manage these side effects effectively.
In conclusion, antineoplastics are a vital category of pharmaceutical APIs used in the treatment of cancer. Through their diverse mechanisms of action, these compounds play a critical role in combating malignancies and improving patient outcomes.
Irinotecan API manufacturers & distributors
Compare qualified Irinotecan API suppliers worldwide. We currently have 19 companies offering Irinotecan API, with manufacturing taking place in 5 different countries. Use the table below to review supplier type, countries of origin, certifications, product portfolio and GMP audit availability.
| Supplier | Type | Country | Product origin | Certifications | Portfolio |
|---|---|---|---|---|---|
| Arch Pharmalabs | Producer | India | India | CoA, USDMF | 19 products |
| AXXO GmbH | Distributor | Germany | World | CoA, GMP, GDP, MSDS, USDMF | 243 products |
| Cipla | Producer | India | India | CEP, CoA, GMP, USDMF, WC | 164 products |
| Emcure Pharma | Producer | India | India | CoA, GMP, USDMF, WC | 80 products |
| Fermion | Producer | Finland | Finland | BSE/TSE, CEP, CoA, GDP, GMP, JDMF, Other, MSDS, USDMF | 29 products |
| Hetero Labs | Producer | India | India | CoA, GMP, USDMF, WC | 90 products |
| Hubei Haosun Pharma | Producer | China | China | CoA, USDMF | 8 products |
| Humble Healthcaare | Producer | India | India | CoA | 30 products |
| Laurus Labs | Producer | India | India | CoA, GMP, USDMF, WC | 50 products |
| LGM Pharma | Distributor | United States | World | BSE/TSE, CEP, CoA, GMP, MSDS, USDMF | 441 products |
| Mac Chem Products | Producer | India | India | CoA, GMP, USDMF, WC | 25 products |
| Polymed Therapeutics | Producer | United States | United States | CoA, USDMF | 11 products |
| Shanghai Desano Chem. | Producer | China | China | CoA, JDMF | 22 products |
| Shanghai Jinhe Bio-Pharma | Producer | China | China | CoA | 12 products |
| Shaoxing Hantai Pharma | Distributor | China | China | CoA | 162 products |
| Shilpa Medicare Ltd | Producer | India | India | BSE/TSE, CEP, CoA, GMP, ISO9001, MSDS, WC | 54 products |
| Sinoway industrial Co.,Lt... | Distributor | China | China | CEP, CoA, GMP, ISO9001, USDMF | 757 products |
| Sun Pharma | Producer | India | India | CoA, USDMF | 219 products |
| Zhejiang Hisun Pharma | Producer | China | China | CoA, USDMF | 69 products |
When sending a request, specify which Irinotecan API quality you need: for example EP (Ph. Eur.), USP, JP, BP, or another pharmacopoeial standard, as well as the required grade (base, salt, micronised, specific purity, etc.).
Use the list above to find high-quality Irinotecan API suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our help page to learn more about sourcing APIs via Pharmaoffer.
Frequently asked questions about Irinotecan API
Sourcing
What matters most when sourcing GMP-grade Irinotecan?
When sourcing GMP‑grade Irinotecan, the priority is verified compliance with US, Canadian, and EU regulatory and GMP requirements. Because supply now comes from many multinational generic manufacturers, confirming the supplier’s quality systems, manufacturing controls, and documentation is essential. It is also important to assess supply reliability in a competitive, patent‑expired market with a broad injectable manufacturing base.
Which documents are typically required when sourcing Irinotecan API?
Request the core API documentation set: CoA (19 companies), USDMF (14 companies), GMP (10 companies), WC (6 companies), CEP (5 companies). Confirm versions and validity dates match the destination market to avoid delays in qualification.
Which manufacturers are known to produce Irinotecan API?
Known or reported manufacturers for Irinotecan: Sinoway industrial Co.,Ltd, LGM Pharma, Shilpa Medicare Ltd, AXXO GmbH. Evaluate their GMP history, scale, and regional coverage before requesting dossiers or allocating demand.
How can I request quotes for Irinotecan API from GMP suppliers?
Submit quote requests through the supplier listings with your specs and required documents (specifications, target volume, delivery timeline, and destination). Providing consistent details upfront speeds comparable offers and clarifies technical feasibility.
Is a GMP audit report available for Irinotecan manufacturers?
Audit reports may be requested for Irinotecan: 5 GMP audit reports available. Confirm the scope and recency of any audit before relying on it for qualification decisions.
How many suppliers offer Irinotecan API on Pharmaoffer?
Reported supplier count for Irinotecan: 19 verified suppliers. Filter listings by certifications, regions, and delivery options to match your qualification plan.
Which countries are known to manufacture Irinotecan API?
Production countries reported for Irinotecan: India (9 producers), China (6 producers), Finland (1 producer). Knowing the manufacturing geography helps anticipate logistics lead times and import compliance needs.
Which certifications do suppliers of Irinotecan usually hold?
Common certifications for Irinotecan suppliers: CoA (19 companies), USDMF (14 companies), GMP (10 companies), WC (6 companies), CEP (5 companies). Always verify issuing authorities and expiry dates when reviewing audit packages.
Technical
What is Irinotecan (CAS 97682-44-5) used for?
Irinotecan is an antineoplastic agent used for metastatic colorectal cancer, commonly in combination with fluorouracil and leucovorin. It is also used with cisplatin for extensive small cell lung cancer and with fluorouracil and leucovorin for metastatic pancreatic adenocarcinoma after progression on gemcitabine-based therapy. Its activity derives from inhibition of topoisomerase I through its active metabolite SN‑38.
Which therapeutic class does Irinotecan fall into?
Irinotecan belongs to the following therapeutic categories: Alkaloids, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, BCRP/ABCG2 Substrates, Carbohydrates. This positioning helps teams compare alternative APIs, anticipate pharmacology expectations, and align early research priorities.
What conditions is Irinotecan mainly prescribed for?
The primary indications for Irinotecan: For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin), Also used in combination with cisplatin for the treatment of extensive small cell lung cancer, Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer, Also used in combination with fluorouracil and leucovorin for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. These use cases frame the target patient populations and help prioritize formulation and safety evaluations.
How does Irinotecan work?
Irinotecan inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex. The formation of this ternary complex interferes with the moving replication fork, which induces replication arrest and lethal double-stranded breaks in DNA. As a result, DNA damage is not efficiently repaired and apoptosis (programmed cell death) occurs.
What should someone know about the safety or toxicity profile of Irinotecan?
Irinotecan’s toxicity is driven by elevated exposure to its active metabolite SN‑38, with neutropenia and late‑onset diarrhea being the primary dose‑limiting effects. It can cause significant gastrointestinal irritation and requires handling practices that minimize aerosolization and mucosal contact. Individuals with reduced UGT1A1 activity are at higher risk for severe hematologic and gastrointestinal toxicity. Additional concerns include cholinergic symptoms, hepatobiliary effects, and interactions with CYP3A or transporter‑modulating agents.
What are important formulation and handling considerations for Irinotecan as an API?
Irinotecan requires formulation as a parenteral solution due to its low aqueous solubility, which necessitates solubilizers to keep the active lactone form in solution. Because the camptothecin lactone ring is sensitive to hydrolysis, handling and dilution should avoid conditions that promote pH‑dependent conversion to the inactive carboxylate. Concentrated solutions are stored and transported under controlled temperatures to limit lactone degradation. Proper preparation and handling help maintain the stability and integrity of the active form.
Is Irinotecan a small molecule?
Irinotecan is classified as a small molecule. That classification shapes process design, impurity profiling, and analytical control strategies.
Are there special stability concerns for oral Irinotecan?
Irinotecan is not developed for oral use, and its known stability considerations apply to parenteral formulations. The lactone ring is hydrolysis‑sensitive and can convert to the inactive carboxylate form in less favorable pH conditions, so formulation and handling conditions are designed to maintain the active lactone. Low aqueous solubility also requires solubilizers to keep the compound in solution. Storage and transport rely on controlled temperatures to limit lactone degradation.
Regulatory
Where is Irinotecan approved or in use globally?
Irinotecan is reported as approved in the following major regions: US, Canada, EU. Understanding geographic coverage informs regulatory filings, supply planning, and risk assessments before escalating procurement.
Pharmaoffer
How does Pharmaoffer’s Smart Sourcing Service help with Irinotecan procurement?
Pharmaoffer's Smart Sourcing Service coordinates compliant suppliers, documentation, and competitive quotes for Irinotecan. It centralizes outreach, follow-ups, and document validation to shorten procurement timelines.
Is Irinotecan included in the PRO Data Insights coverage?
PRO Data Insights coverage for Irinotecan: 636 verified transactions across 209 suppliers and 122 buyers worldwide. Use the dataset to benchmark suppliers and monitor regulatory activity where available.
Where can I access the API market report for Irinotecan?
Market report availability for Irinotecan: Report Available. The report highlights demand trends, pricing drivers, and supplier landscape insights for procurement planning.
